Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093476 | 0.88 | TP53 (0.65) | TP53CSNK2A1GAAALDH1A1KDM4E | |
| SCHEMBL30251615 | 0.88 | TP53 (0.65) | TP53CSNK2A1GAAALDH1A1KDM4E | |
| SCHEMBL18706005 | 0.87 | CSNK2A1 (0.54) | TP53CSNK2A1CSNK2A2CSNK2BALDH1A1 | |
| SCHEMBL29893021 | 0.87 | CSNK2A1 (0.54) | TP53CSNK2A1CSNK2A2CSNK2BALDH1A1 | |
| SCHEMBL5518393 | 0.86 | ALDH1A1 (0.53) | TP53ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL9945609 | 0.85 | KDM4E (0.52) | TP53CSNK2A1GAACSNK2A2CSNK2B | |
| SCHEMBL19764532 | 0.84 | GAA (0.54) | TP53CSNK2A1GAACSNK2A2CSNK2B | |
| SCHEMBL20504398 | 0.83 | TDP1 (0.51) | CSNK2A1GAACSNK2A2CSNK2BALDH1A1 | |
| SCHEMBL31000776 | 0.83 | TDP1 (0.51) | CSNK2A1GAACSNK2A2CSNK2BALDH1A1 | |
| SCHEMBL18705726 | 0.82 | CSNK2A1 (0.50) | TP53CSNK2A1CSNK2A2CSNK2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-118401507-A | Inhibitors targeting ubiquitin-specific protease 7 (USP 7) | 丹娜法伯癌症研究院 | 2024-07-26 | — | — | CN | disclosed |
| EP-4373816-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023003973-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| CN-108463458-B | Modulators of ROR-gamma | 生命医药有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3377482-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | TP53 4309/4885CSNK2A1 170/4885GAA 694/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | TP53 4309/4885CSNK2A1 170/4885GAA 694/4885 |
| US-20240376076-A1 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | USP7, USP47, USP2 | TP53 361/4885CSNK2A1 429/4885GAA 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.